tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year
PremiumThe FlyAptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year
5M ago
Aptose Biosciences (APTO) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Aptose Biosciences (APTO) Q4 Earnings Cheat Sheet
5M ago
Aptose Biosciences Regains Nasdaq Bid Price Compliance
Premium
Company Announcements
Aptose Biosciences Regains Nasdaq Bid Price Compliance
5M ago
Aptose Biosciences Advances TUSCANY Trial Dosage Escalation
PremiumCompany AnnouncementsAptose Biosciences Advances TUSCANY Trial Dosage Escalation
6M ago
Aptose Biosciences approved to escalate dose in Phase 1/2 AML trial
Premium
The Fly
Aptose Biosciences approved to escalate dose in Phase 1/2 AML trial
6M ago
Aptose Biosciences Announces Reverse Share Split
Premium
Company Announcements
Aptose Biosciences Announces Reverse Share Split
6M ago
Aptose Biosciences Establishes $25M Equity Facility
PremiumCompany AnnouncementsAptose Biosciences Establishes $25M Equity Facility
6M ago
Promising Results from Aptose Biosciences’ TUSCANY Trial Boost Joseph Pantginis’ Buy Rating
Premium
Ratings
Promising Results from Aptose Biosciences’ TUSCANY Trial Boost Joseph Pantginis’ Buy Rating
6M ago
Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment
Premium
Company Announcements
Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100